바이러스성 간질환 치료약

• 영문명: Drugs for the Treatment of Viral Hepatitis
• 발행기관: 대한약학회
• 저자명: 김충섭
• 간행물 정보: 『약학회지』제57권 제1호 (2013년), 43~54쪽, 전체 12쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2013.02.28

영문 초록

Viral hepatitis is the inflammation of liver cells caused by viruses, and still one of the major health-care prob-lems worldwide. A number of viruses to cause hepatitis are type A, B, C, D, E or G. Among these viruses leading to hep- atitis, B and C are more troublesome being more prone to chronic illness which can cause the potentially fatal ditions of hepatocellular carcinoma (HCC) and/or liver failure. If immediate treatment is not initiated, liver transplant is the only option left. Over the past few decades there has been remarkable progress in diagnose and monitor all hepatitis virus infec-tions for treatment and prevention. Nonetheless, important challenges remain to develop more effective and safe vaccines for prevention as well as antiviral agents to reduce viremia/viral load by inhibiting viral replication. The ment and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years has heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus. The introduction of Direct Acting Antivirals (DDAs) for the treatment of HBV carriers has permitted the long term use of hese compounds for the continuous suppression of viral replication. This review aims to summarize the current status and development approaches of antiviral drugs for the treatment of viral hepatitis and future erspectives.

목차

감사의 말씀

참고문헌

키워드

Viral hepatitis A, B, C, D, or G Directing Acting Antivirals (DAA)